PURPOSE: To explore whether or not there is an association between the presence of either of the germline mutations in the MutY human homologue (MYH) gene (Y165C and G382D) and the risk of breast cancer. METHODS: 691 breast cancer patients and 812 healthy controls were genotyped for the MYH Y165C and G382D mutations. The frequencies of heterozygotes, homozygotes and compound heterozygotes were compared for the two groups. RESULTS: Four (0.6%) of 691 breast cancer cases carried a MYH Y165C mutant allele, compared to five (0.6%) of the controls (OR 1.1, 95%CI 0.29-4.0, P=0.9). Eight (1.2%) cases carried a MYH G382D mutant allele, compared to eight (1.0%) of the controls (OR 1.2, 95%CI 0.44-3.3, P=0.7). No case or control was homozygous for the variant and none were compound heterozygotes. CONCLUSION: Carriers of the MYH Y165C or G382D mutant alleles do not appear to be at increased risk for breast cancer.
PURPOSE: To explore whether or not there is an association between the presence of either of the germline mutations in the MutY human homologue (MYH) gene (Y165C and G382D) and the risk of breast cancer. METHODS: 691 breast cancerpatients and 812 healthy controls were genotyped for the MYHY165C and G382D mutations. The frequencies of heterozygotes, homozygotes and compound heterozygotes were compared for the two groups. RESULTS: Four (0.6%) of 691 breast cancer cases carried a MYHY165C mutant allele, compared to five (0.6%) of the controls (OR 1.1, 95%CI 0.29-4.0, P=0.9). Eight (1.2%) cases carried a MYHG382D mutant allele, compared to eight (1.0%) of the controls (OR 1.2, 95%CI 0.44-3.3, P=0.7). No case or control was homozygous for the variant and none were compound heterozygotes. CONCLUSION: Carriers of the MYHY165C or G382D mutant alleles do not appear to be at increased risk for breast cancer.
Authors: Aung Ko Win; Sean P Cleary; James G Dowty; John A Baron; Joanne P Young; Daniel D Buchanan; Melissa C Southey; Terrilea Burnett; Patrick S Parfrey; Roger C Green; Loïc Le Marchand; Polly A Newcomb; Robert W Haile; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins Journal: Int J Cancer Date: 2011-04-08 Impact factor: 7.396
Authors: Amanda Bartenbaker Thompson; Erin G Sutcliffe; Kevin Arvai; Maegan E Roberts; Lisa R Susswein; Megan L Marshall; Rebecca Torene; Kristen J Vogel Postula; Kathleen S Hruska; Shaochun Bai Journal: Fam Cancer Date: 2022-01-04 Impact factor: 2.375
Authors: Astrid A Out; Marijke Wasielewski; Petra E A Huijts; Ivonne J H M van Minderhout; Jeanine J Houwing-Duistermaat; Carli M J Tops; Maartje Nielsen; Caroline Seynaeve; Juul T Wijnen; Martijn H Breuning; Christi J van Asperen; Mieke Schutte; Frederik J Hes; Peter Devilee Journal: Breast Cancer Res Treat Date: 2012-07 Impact factor: 4.872
Authors: Ewout P Boesaard; Ingrid P Vogelaar; Peter Bult; Carla Ap Wauters; J Han Jm van Krieken; Marjolijn Jl Ligtenberg; Rachel S van der Post; Nicoline Hoogerbrugge Journal: Hered Cancer Clin Pract Date: 2014-12-12 Impact factor: 2.857
Authors: Aung Ko Win; Jeanette C Reece; James G Dowty; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Melissa C Southey; Joanne P Young; Sean P Cleary; Hyeja Kim; Michelle Cotterchio; Finlay A Macrae; Katherine M Tucker; John A Baron; Terrilea Burnett; Loïc Le Marchand; Graham Casey; Robert W Haile; Polly A Newcomb; Stephen N Thibodeau; John L Hopper; Steven Gallinger; Ingrid M Winship; Noralane M Lindor; Mark A Jenkins Journal: Int J Cancer Date: 2016-06-02 Impact factor: 7.316
Authors: Katie A Ashton; Anthony Proietto; Geoffrey Otton; Ian Symonds; Rodney J Scott Journal: Hered Cancer Clin Pract Date: 2009-01-26 Impact factor: 2.857
Authors: Kara N Maxwell; Bradley Wubbenhorst; Kurt D'Andrea; Bradley Garman; Jessica M Long; Jacquelyn Powers; Katherine Rathbun; Jill E Stopfer; Jiajun Zhu; Angela R Bradbury; Michael S Simon; Angela DeMichele; Susan M Domchek; Katherine L Nathanson Journal: Genet Med Date: 2014-12-11 Impact factor: 8.822